Welcome to our dedicated page for In8Bio news (Ticker: INAB), a resource for investors and traders seeking the latest updates and insights on In8Bio stock.
Overview of IN8Bio, Inc.
IN8Bio, Inc. (Nasdaq: INAB) is a clinical-stage biotechnology company pioneering the development of gamma-delta T cell-based immunotherapies for the treatment of solid and liquid tumors. Leveraging the unique properties of gamma-delta T cells, the company focuses on creating innovative therapies that address significant unmet medical needs in oncology. Gamma-delta T cells are a specialized subset of T cells with the innate ability to differentiate between healthy and diseased tissues, making them a promising tool for targeted cancer treatment.
Core Business and Technology
IN8Bio's proprietary DeltEx platform employs allogeneic, autologous, and genetically modified approaches to develop gamma-delta T cell therapies. These therapies are designed to enhance tumor targeting, improve treatment durability, and reduce the risk of toxicities often associated with other immunotherapies. Unlike traditional CAR-T therapies, gamma-delta T cells naturally secrete lower levels of inflammatory cytokines, potentially offering a safer and more tolerable treatment option.
Key Clinical Programs
- INB-400: A Phase 2 clinical program targeting newly diagnosed glioblastoma (GBM), a highly aggressive brain tumor with limited treatment options. INB-400 combines autologous gamma-delta T cells with the standard-of-care regimen to improve progression-free and overall survival rates.
- INB-100: A Phase 1 program focused on high-risk leukemia patients undergoing hematopoietic stem cell transplantation. This therapy utilizes haplo-matched allogeneic gamma-delta T cells to reduce relapse rates and improve long-term outcomes.
- Preclinical Pipeline: The company is also exploring additional product candidates, such as INB-200 and INB-300, targeting other solid and hematologic tumors.
Market Position and Differentiation
IN8Bio operates within the competitive landscape of cell-based immunotherapies, which includes CAR-T therapies and other T cell-based approaches. However, the company differentiates itself through its focus on gamma-delta T cells, which offer unique advantages such as innate tumor recognition and reduced risk of severe toxicities like cytokine release syndrome (CRS). This positions IN8Bio as a potential leader in the next generation of immunotherapies.
Challenges and Opportunities
As a clinical-stage company, IN8Bio faces challenges such as regulatory hurdles, manufacturing scalability, and the inherent risks of clinical development. However, its innovative approach and focus on addressing unmet medical needs provide significant opportunities for growth and impact within the biopharmaceutical industry.
Conclusion
IN8Bio, Inc. represents a cutting-edge approach to cancer treatment, utilizing the unique properties of gamma-delta T cells to develop therapies with the potential to transform outcomes for patients with difficult-to-treat cancers. Through its robust pipeline and proprietary technology, the company is well-positioned to make a meaningful impact in the field of oncology.
IN8bio, a clinical-stage biopharmaceutical company listed on Nasdaq as INAB, announced its participation in the International Society for Cell & Gene Therapy (ISCT) 2024 from May 28 to June 1 in Vancouver, Canada. IN8bio will present multiple findings on their gamma-delta T cell therapies. Dr. Kate Rochlin, COO, emphasized the significance of these presentations in advancing their proprietary manufacturing platform. Highlights include the INB-400 DeltEx drug-resistant immunotherapy (DRI) multi-center clinical trial and analyses comparing healthy donor and patient-manufactured autologous DeltEx DRI products. These developments are poised to improve cancer patient outcomes by targeting and potentially eradicating cancer cells.
IN8bio announced the upcoming presentation of updated Phase 1 study results for INB-200 at the 2024 ASCO Annual Meeting. INB-200, an autologous Drug Resistant Immunotherapy (DeltEx DRI), is being evaluated as a first-line treatment for newly diagnosed glioblastoma multiforme (GBM). The study involved 23 patients and showed promising progression-free survival (PFS) rates beyond the median expected with standard treatment. There were no dose-limiting toxicities, although some patients experienced adverse events like decreased white blood cell count and fatigue. The presentation will take place on June 1, 2024.
IN8bio (Nasdaq: INAB), a clinical-stage biopharmaceutical company, announced it will present updated interim results from their Phase 1 trial of INB-100 at the upcoming European Hematology Association (EHA) 2024 Congress in Madrid, June 13-16. INB-100 is a gamma-delta T cell therapy aimed at increasing survival and reducing cancer recurrence in leukemia patients post-haploidentical stem cell transplantation, without severe graft-versus-host disease. The presentation will be held on June 14, 2024, at 10:00 a.m. CEST by Dr. Joseph P. McGuirk. Abstracts are accessible on the EHA website, and the poster will be available on IN8bio's site following the session.
IN8bio presented details about its robust and reproducible gamma-delta T cell therapy manufacturing platform at ASGCT 2024. The data demonstrate significant advancements in the characterization of gamma-delta T cell-based therapies, showing increased potency, effector functions, and trafficking capabilities. The study evaluated T cell products from healthy donors and GBM patients, revealing consistent profiles and gene expression changes throughout the manufacturing process.
IN8bio, Inc. (Nasdaq: INAB) reported financial results for Q1 2024, highlighting progress in gamma-delta T cell programs. Key points include preclinical data on nsCAR platform targeting cancer cells, peer-reviewed publication on DeltEx Drug Resistant Immunotherapy for GBM, and dosing first patient in Phase 2 clinical trial. Financially, R&D expenses increased to $4.9 million, G&A expenses were $3.7 million, net loss was $8.6 million, and cash position stood at $13.0 million.
IN8bio, Inc. (Nasdaq: INAB) has dosed the first patient in a Phase 2 clinical trial of INB-400 for newly diagnosed glioblastoma multiforme (GBM). INB-400 is an autologous gamma-delta T cell therapy genetically engineered to survive chemotherapy and enhance cancer cell killing. The trial, expected to enroll up to 40 patients, aims to evaluate safety, tolerability, and overall survival rate at 12 months. INB-400 was granted Orphan Drug Designation in 2023 and is designed to work alongside standard-of-care treatments like temozolomide.
FAQ
What is the current stock price of In8Bio (INAB)?
What is the market cap of In8Bio (INAB)?
What is IN8Bio, Inc.'s primary focus?
What are gamma-delta T cells?
What are IN8Bio's key clinical programs?
How does IN8Bio differentiate itself from competitors?
What challenges does IN8Bio face?
What is the DeltEx platform?
What types of cancers does IN8Bio target?
What is INB-400?
What is the significance of INB-100?
What makes gamma-delta T cell therapies safer than CAR-T therapies?
